Relmada Therapeutics Inc (NAS:RLMD)
$ 3.05 -0.06 (-1.93%) Market Cap: 92.03 Mil Enterprise Value: 10.23 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 31/100

Relmada Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 07:00PM GMT
Release Date Price: $2.81 (-1.06%)
Andrew Tsai
Jefferies LLC - Analyst

Okay. We're going to get started with our next session. Hi, everyone. I'm Andrew Tsai, senior biotech analyst here at Jefferies. Thanks for tuning in, and it's my pleasure to have the Relmada team joining me today. I have to the left of me, Sergio Traversa, CEO; and to the left of him, Cedric O'Gorman, CMO. Welcome both of you.

Cedric O;Gorman
Relmada Therapeutics, Inc. - Chief Medical Officer

' -

Thank you.

Andrew Tsai
Jefferies LLC - Analyst

So maybe Sergio, Cedric, for those in the audience who are less familiar with the Relmada story, could you possibly give us an overview about your company, what you're trying to achieve, what stage of development you're in and the next set of catalysts we can expect over the coming months?

Sergio Traversa
Relmada Therapeutics, Inc. - CEO

Okay. Well, first, Andrew, thank you very much for inviting us at the Jefferies conference. And welcome, everyone interested. And thanks for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot